A phase I trial of XEN 1101 for the treatment of epilepsy

Trial Profile

A phase I trial of XEN 1101 for the treatment of epilepsy

Planning
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs XEN 1101 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; First in man
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 New trial record
    • 26 Apr 2017 According to a Xenon Pharmaceuticals media release, the company expects pharmacodynamics read-out from this trial in the first quarter of 2018.
    • 26 Apr 2017 According to a Xenon Pharmaceuticals media release, the company anticipates an Investigational New Drug (IND) application or IND equivalent for XEN-1101 to initiate this phase I trial in the fourth quarter of 217.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top